View in EDS HTML Full Text PDF Full Text

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Authors: Teng E; Early Clinical Development, Genentech Inc, South San Francisco, California., Manser PT; Biostatistics, Genentech Inc, South San Francisco, California., Pickthorn K; Early Clinical Development, Genentech Inc, South San Francisco, California., Brunstein F; Product Development Safety, Genentech Inc, South San Francisco, California., Blendstrup M; Clinical Operations, Genentech Inc, South San Francisco, California., Sanabria Bohorquez S; Clinical Imaging Group, Genentech Inc, South San Francisco, California., Wildsmith KR; Biomarker Development, Genentech Inc, South San Francisco, California.; Now with Eisai Inc, Woodcliff Lake, New Jersey., Toth B; Biostatistics, Genentech Inc, South San Francisco, California., Dolton M; Roche Products Pty Limited, Sydney, Australia., Ramakrishnan V; Clinical Pharmacology, Genentech Inc, South San Francisco, California., Bobbala A; Product Development Safety, Genentech Inc, South San Francisco, California., Sikkes SAM; Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center, VU University Amsterdam, Amsterdam, the Netherlands.; Department of Clinical, Neuro- and Developmental Psychology, VU University, Amsterdam, the Netherlands., Ward M; Early Clinical Development, Genentech Inc, South San Francisco, California.; Now with Alector Inc, South San Francisco, California., Fuji RN; Safety Assessment, Genentech Inc, South San Francisco, California., Kerchner GA; F. Hoffmann-La Roche AG, Basel, Switzerland.
Corporate Authors: Tauriel Investigators
Source: JAMA neurology [JAMA Neurol] 2022 Aug 01; Vol. 79 (8), pp. 758-767.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35696185
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Teng+E%22">Teng E</searchLink>; Early Clinical Development, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Manser+PT%22">Manser PT</searchLink>; Biostatistics, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Pickthorn+K%22">Pickthorn K</searchLink>; Early Clinical Development, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Brunstein+F%22">Brunstein F</searchLink>; Product Development Safety, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Blendstrup+M%22">Blendstrup M</searchLink>; Clinical Operations, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Sanabria+Bohorquez+S%22">Sanabria Bohorquez S</searchLink>; Clinical Imaging Group, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Wildsmith+KR%22">Wildsmith KR</searchLink>; Biomarker Development, Genentech Inc, South San Francisco, California.; Now with Eisai Inc, Woodcliff Lake, New Jersey.<br /><searchLink fieldCode="AU" term="%22Toth+B%22">Toth B</searchLink>; Biostatistics, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Dolton+M%22">Dolton M</searchLink>; Roche Products Pty Limited, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Ramakrishnan+V%22">Ramakrishnan V</searchLink>; Clinical Pharmacology, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Bobbala+A%22">Bobbala A</searchLink>; Product Development Safety, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Sikkes+SAM%22">Sikkes SAM</searchLink>; Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center, VU University Amsterdam, Amsterdam, the Netherlands.; Department of Clinical, Neuro- and Developmental Psychology, VU University, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Ward+M%22">Ward M</searchLink>; Early Clinical Development, Genentech Inc, South San Francisco, California.; Now with Alector Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Fuji+RN%22">Fuji RN</searchLink>; Safety Assessment, Genentech Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Kerchner+GA%22">Kerchner GA</searchLink>; F. Hoffmann-La Roche AG, Basel, Switzerland.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Tauriel+Investigators%22">Tauriel Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101589536%22">JAMA neurology</searchLink> [JAMA Neurol] 2022 Aug 01; Vol. 79 (8), pp. 758-767.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101589536 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2168-6157 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221686149%22">21686149 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Neurol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35696185
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1001/jamaneurol.2022.1375
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 758
    Titles:
      – TitleFull: Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Teng E
      – PersonEntity:
          Name:
            NameFull: Manser PT
      – PersonEntity:
          Name:
            NameFull: Pickthorn K
      – PersonEntity:
          Name:
            NameFull: Brunstein F
      – PersonEntity:
          Name:
            NameFull: Blendstrup M
      – PersonEntity:
          Name:
            NameFull: Sanabria Bohorquez S
      – PersonEntity:
          Name:
            NameFull: Wildsmith KR
      – PersonEntity:
          Name:
            NameFull: Toth B
      – PersonEntity:
          Name:
            NameFull: Dolton M
      – PersonEntity:
          Name:
            NameFull: Ramakrishnan V
      – PersonEntity:
          Name:
            NameFull: Bobbala A
      – PersonEntity:
          Name:
            NameFull: Sikkes SAM
      – PersonEntity:
          Name:
            NameFull: Ward M
      – PersonEntity:
          Name:
            NameFull: Fuji RN
      – PersonEntity:
          Name:
            NameFull: Kerchner GA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2022 Aug 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2168-6157
          Numbering:
            – Type: volume
              Value: 79
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: JAMA neurology
              Type: main
ResultId 1